Valuation : Stereotaxis, Inc.

Market Cap 144M 124M 117M 106M 200M 13.73B 201M 1.38B 538M 6.96B 542M 530M 23.05B P/E 2026 *
-7.08x
P/E 2027 * -9.82x
Enterprise Value 144M 124M 117M 106M 200M 13.73B 201M 1.38B 538M 6.96B 542M 530M 23.05B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 3.16x
Free-Float
78.85%
Yield 2026 *
-
Yield 2027 * -
1 day-0.69%
1 week+1.41%
1 month+14.29%
3 months-27.27%
6 months-33.33%
Current year-37.39%
1 week 1.39
Extreme 1.39
1.51
1 month 1.29
Extreme 1.29
1.51
Current year 1.24
Extreme 1.24
2.86
1 year 1.24
Extreme 1.24
3.59
3 years 1.24
Extreme 1.24
3.59
5 years 1.24
Extreme 1.24
7.22
10 years 0.47
Extreme 0.47
10.3
Manager TitleAgeSince
Chief Executive Officer - 03/02/2017
Director of Finance/CFO 57 01/10/2019
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 79 01/02/2005
Chairman - 03/02/2017
Director/Board Member 71 29/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 A Free

Director

43,103 0.0441%
7/1/26 A Free

Director

43,103 0.0441%
7/1/26 A
DAFNA Capital Management LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.69%+1.41%-50.00%-15.29% 144M
-0.82%-1.85%+25.24%+10.77% 228B
-1.16%-0.72%+3.76%-19.41% 150B
+1.14%+0.88%-19.66%+20.53% 133B
+3.12%-1.45%-54.22%-10.46% 70B
+0.60%+0.28%+11.57%+18.67% 52.31B
-0.99%-3.12%-17.97%-15.39% 50.59B
-0.18%+0.08%+22.20%+26.84% 43.3B
-0.01%+0.94%+37.39%+47.66% 40.74B
-0.10%+3.29%-12.54%+50.45% 34.63B
Average +0.18%-0.54%-5.42%+11.44% 80.31B
Weighted average by Cap. +0.03%-1.02%+2.06%+8.21%

Financials

2026 *2027 *
Net sales 34.33M 29.56M 27.76M 25.34M 47.6M 3.27B 47.94M 329M 128M 1.66B 129M 126M 5.48B 45.67M 39.32M 36.92M 33.7M 63.31M 4.35B 63.76M 437M 170M 2.2B 171M 168M 7.3B
Net income -20.13M -17.33M -16.28M -14.86M -27.91M -1.92B -28.11M -193M -75.04M -971M -75.59M -73.95M -3.22B -14.77M -12.71M -11.94M -10.9M -20.47M -1.41B -20.62M -141M -55.04M -712M -55.44M -54.24M -2.36B
Net Debt - -
Logo Stereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters.
Employees
131
Date Price Change Volume
31/08/26 $1.440 -0.69% 593,115
28/08/26 $1.450 -1.36% 289,611
27/08/26 $1.470 +1.38% 472,972
26/08/26 $1.450 +2.84% 583,277
25/08/26 $1.410 -0.70% 402,906
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.440USD
Average target price
3.000USD
Spread / Average Target
+108.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STXS Stock